Abstract: The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, said recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against said RNA virus or against both measles virus and against said RNA virus. It also relates to the use of said recombinant measles virus for the preparation of immunogenic composition.
Type:
Grant
Filed:
February 9, 2018
Date of Patent:
December 31, 2019
Assignees:
INSTlTUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFlQUE
Abstract: 2? and/or 3? prodrugs of 1?, 2?, 3? or 4?-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.
Type:
Application
Filed:
January 2, 2014
Publication date:
April 24, 2014
Applicants:
Idenix Pharmaceuticals, Inc., L'Universite Montpellier II, Centre National de la Recherche Scientiflque, Universita degli Studi di Cagliari
Inventors:
Richard Storer, Gilles Gosselin, Jean-Pierre Sommadossi, Paolo LaColla